No Data
Applied Therapeutics CRL a 'Major Setback,' Says William Blair
RBC Downgrades Applied Therapeutics to Sector Perform From Outperform, Cuts Price Target to $4 From $12, Keeps Speculative Risk
Applied Therapeutics Receives Complete Response Letter From U.S. FDA Regarding New Drug Application For Govorestat For Classic Galactosemia
Regulatory Setback For Applied Therapeutics' Lead Program, FDA Highlights Deficiencies In Clinical Application
Express News | Applied Therapeutics Inc : RBC Cuts to Sector Perform From Outperform; Cuts Target Price to $4 From $12
Wait for Galactosemia Therapy Goes on After FDA Shuns Applied Therapeutics' Govorestat
No Data
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
